Importance of response to neoadjuvant therapy in patients with liver-limited mCRC when the intent is resection and/or ablation.
This review article provides an overview of treatment options for patients with liver metastases, with a focus on the importance of response rates on resectability. The inclusion of surgery provides the only potential for cure in this setting. There are several important surgical considerations for performing resections, and close communication between oncologists and surgeons is important for achieving the intended outcome. In patients with initially unresectable colorectal liver metastases, an association between tumor response rate and resection rates has been demonstrated, implying that greater response rates could increase resection rates. Neoadjuvant chemotherapy establishes expected response rates with the use of biologic agents, such as cetuximab or bevacizumab, further improving the response rate and potentially increasing the rate of resection and potential to cure the disease.
The Center for Cancer Prevention and Treatment, St Joseph Hospital, Orange, CA. Electronic address: Lawrence.Wagman@stjoe.org.
Lawrence D
LD
Wagman
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D020360:Neoadjuvant Therapy / Q000379:methods*; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Biochemotherapy; Colorectal cancer; Liver metastases; Neoadjuvant; Resection